Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038447 | 1.00 | CYP3A4 (0.45) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL12251962 | 1.00 | CYP3A4 (0.45) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL14275833 | 0.89 | MAPT (0.38) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL15130648 | 0.89 | MAPT (0.38) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL15130699 | 0.87 | CYP3A4 (0.37) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL4701570 | 0.87 | CYP3A4 (0.37) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL9255336 | 0.83 | — | — | |
| SCHEMBL318757 | 0.83 | — | — | |
| SCHEMBL16190279 | 0.83 | — | — | |
| SCHEMBL30877547 | 0.82 | CYP3A4 (0.47) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-0473585-A4 | ADHESIVE COMPOSITION | — | 1993-02-17 | — | — | EP | disclosed |
| EP-0521934-A4 | COPOLYMERS OF MALEIC ANHYDRIDE AND ACRYLIC ACID USEFUL IN DENTURE ADHESIVES | — | 1993-02-17 | — | — | EP | disclosed |
| EP-0517863-A4 | TERPOLYMERS OF MALEIC ANHYDRIDE, C 1?-C 5? ALKYL VINYL ETHER AND ISOBUTYLENE OR A C 12?-C 14? ALPHA-OLEFIN, AND CROSSLINKED PRODUCTS THEREOF | — | 1993-01-27 | — | — | EP | disclosed |
| EP-0521934-A1 | COPOLYMERS OF MALEIC ANHYDRIDE AND ACRYLIC ACID USEFUL IN DENTURE ADHESIVES | ISP INVESTMENTS INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0517863-A1 | TERPOLYMERS OF MALEIC ANHYDRIDE, C 1?-C 5? ALKYL VINYL ETHER AND ISOBUTYLENE OR A C 12?-C 14? ALPHA-OLEFIN, AND CROSSLINKED PRODUCTS THEREOF | ISP INVESTMENTS INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0473585-A1 | ADHESIVE COMPOSITION | ISP INVESTMENTS INC. (US) | 1992-03-11 | — | — | EP | disclosed |
| WO-1992001724-A1 | TERPOLYMERS OF MALEIC ANHYDRIDE, C1-C5 ALKYL VINYL ETHER AND ISOBUTYLENE OR A C12-C14 ALPHA-OLEFIN, AND CROSSLINKED PRODUCTS THEREOF | ISP INVESTMENTS INC. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991014716-A1 | COPOLYMERS OF MALEIC ANHYDRIDE AND ACRYLIC ACID USEFUL IN DENTURE ADHESIVES | ISP INVESTMENTS INC. (US) | 1991-10-03 | — | — | WO | disclosed |
| WO-1990011325-A1 | ADHESIVE COMPOSITION | GAF CHEMICALS CORPORATION (US) | 1990-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CYP3A4 481/4885TSHR 1660/4885TDP1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.